Endostatin

Generic Name: Endostatin

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 187888-07-9

Unique Ingredient Identifier: 67RHC0R671

Indication: Investigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma

Phase 4

Conditions: Adenocarcinoma of Lung

Interventions: Drug: pemetrexed plus cisplatin or carboplatin
Drug: recombinant human endostatin

First Posted Date: 2016-06-17

Last Posted Date: 2016-06-21

Lead Sponsor: Anhui Provincial Hospital

Target Recruit Count: 100

Registration Number: NCT02804646

Locations: 🇨🇳
Anhui provincial hospital, Hefei, Anhui, China

Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients.

Phase 2

Conditions: Esophageal Cancer
Endostatin

Interventions: Drug: Endostatins
Drug: Oxaliplatin
Radiation: Radiotherapy

First Posted Date: 2016-04-20

Last Posted Date: 2016-04-20

Lead Sponsor: Hangzhou Cancer Hospital

Target Recruit Count: 22

Registration Number: NCT02745561

Locations: 🇨🇳
Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China

Endostar for Locally Recurrent Nasopharyngeal Carcinoma

Phase 2

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Endostatins
Radiation: IMRT

First Posted Date: 2015-12-21

Last Posted Date: 2021-02-03

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 96

Registration Number: NCT02636231

Locations: 🇨🇳
Cancer Center of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳
The First Hospital of Gannan Medical University, GanZhou, Jiangxi, China
🇨🇳
The First Affiliated Hospital of Clinical Medicine of G.D.P.U., Guangzhou, Guangdong, China

and more 5 locations

E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck

Phase 3

Conditions: Head and Neck Neoplasms

Interventions: Drug: Endostatins
Drug: Paclitaxel injection
Drug: Cisplatin injection

First Posted Date: 2015-12-15

Last Posted Date: 2015-12-15

Lead Sponsor: Guangzhou Double Bioproducts Co., Ltd

Target Recruit Count: 540

Registration Number: NCT02630264

Locations: 🇨🇳
Guangzhou DB, Gaungzhou, Guangdong, China

Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC

Phase 4

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Endostatin
Drug: Vinorelbine
Drug: Cisplatin

First Posted Date: 2015-07-14

Last Posted Date: 2015-07-14

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT02497118

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.

Phase 2

Conditions: Lung Cancer

Interventions: Drug: Placebo
Drug: Recombinant human endostatin

First Posted Date: 2015-01-29

Last Posted Date: 2015-01-29

Lead Sponsor: Peking University Third Hospital

Target Recruit Count: 60

Registration Number: NCT02350361

Locations: 🇨🇳
Peking University Third Hospital, Beijing, China

Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Phase 2

Completed

Conditions: Vestibular Schwannoma
Neurofibromatosis Type 2

Interventions: Drug: Endostatin

First Posted Date: 2014-04-04

Last Posted Date: 2017-02-09

Lead Sponsor: Beijing Tiantan Hospital

Target Recruit Count: 20

Registration Number: NCT02104323

Locations: 🇨🇳
Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, Beijing, China

Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC

Phase 2

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Bevacizumab
Drug: recombinant human endostatin

First Posted Date: 2013-12-09

Last Posted Date: 2013-12-20

Lead Sponsor: Zhejiang University

Target Recruit Count: 20

Registration Number: NCT02005120

Locations: 🇨🇳
Qiong Zhao, Hangzhou, Zhejiang, China
🇨🇳
The first affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China

Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB

Phase 3

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Docetaxel
Drug: Pemetrexed
Drug: Cis-platinum
Drug: rh-Endostatin

First Posted Date: 2013-12-04

Last Posted Date: 2013-12-04

Lead Sponsor: Xinjiang Medical University

Target Recruit Count: 392

Registration Number: NCT02001168

Locations: 🇨🇳
Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China

Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC

Phase 1

Completed

Conditions: Stage III Non-small-Cell Lung Cancer

Interventions: Drug: Recombinant human endostatin
Drug: Etoposide (50mg/m2) IV (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles
Drug: cisplatinum (50mg/m2) IV (in the vein) on day 1 and day 8 of a 28-day cycle for 2 cycles
Other: laboratory biomarker analysis
Other: CT perfusion imaging

First Posted Date: 2012-11-27

Last Posted Date: 2017-07-14

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 73

Registration Number: NCT01733589

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy